Grant Bogle
2020 ALI Fellow
Prior to ALI, Grant Bogle was senior vice president and chief commercial officer of TESARO, a publicly traded developer of cancer-focused drugs acquired by GlaxoSmithKline. Earlier he served as senior vice president of pharmaceutical and biotech solutions at McKesson Specialty Health/U.S. Oncology, and was a senior executive at Millennium Pharmaceuticals, Viacord, Roche, and Knoll Pharmaceutical Company.
Grant serves on the board of the American School for the Deaf, the oldest permanent school for the deaf in the United States, as well as Epizyme, Inc., a Boston-based biotechnology company developing targeted epigenetic therapies for people living with cancer.